Financial results for the period ended Jun 30, 2026
As filed · Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactThe Board of Directors of Sudeep Pharma Limited approved the Unaudited Standalone and Consolidated Financial Results for the first quarter ended on 30th June 2026 during a meeting held on 4th August 2026. The meeting commenced at 03:40 p.m. and concluded at 5:50 p.m.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
RevisedWe are also making great progress on our Sudeep Advanced Materials (SAM) project, in line with our planned timelines to commission by March 2027.
Encouraged by strong customer engagement and increasing visibility on future off-take opportunities, we have initiated planning for Phase 2, reinforcing our confidence in the long-term growth potential of the advanced battery materials business.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- we have a significant project pipeline at NSS, which we will see come through in FY '27. (management committed by FY27)
- the expansion that we are doing with the Greenfield will add capacity to the pharma food nutrition business ve (management committed by FY27)
Evidence
- Sudeep Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q2 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%